Bioorthogonal ECM Functionalization for Decellularized Organ Scaffolds

The patent applies local quality by using bioorthogonal chemistry to achieve selective functionalization at specific locations within the extracellular matrix. Instead of random crosslinking throughout the entire scaffold, the method targets specific regions containing glycosaminoglycans or other biomolecules, leaving the rest of the matrix structure unchanged. This localized approach allows immobilization of biologically active molecules while preserving the original mechanical and biochemical features of the biomaterial.

The patent employs parameter changes by introducing bioorthogonal chemical groups (such as azides or alkynes) that can be selectively reacted with specific biomolecules in the extracellular matrix. These chemical parameters are designed to be orthogonal to native biological processes, allowing controlled functionalization without altering the overall structure or properties of the scaffold. The reaction conditions and chemical parameters are optimized to maintain the integrity of the biomaterial while achieving the desired functionalization.

The patent applies composite materials by combining the structural advantages of synthetic meshes with the infection-resistant properties of biologic materials. The method involves functionalizing decellularized organ scaffolds (which provide infection resistance) with biologically active molecules that enhance mechanical strength and promote tissue integration. This creates a composite structure that integrates the best properties of both synthetic and biologic materials, achieving both strength and low infection rates.

The patent uses an intermediary approach by employing decellularized organ scaffolds as a intermediate material that bridges synthetic and biologic options. These scaffolds serve as a mediator that provides the structural integrity needed for mesh strength while maintaining the infection resistance of biologic materials. The scaffolds are then further functionalized with biologically active molecules to enhance their performance, creating a multi-functional intermediate solution.

The patent applies preliminary action by pre-functionalizing the decellularized organ scaffolds with biologically active molecules before implantation. This preliminary functionalization ensures that the scaffold is already optimized for promoting tissue integration and resisting bacterial colonization at the time of implantation. The scaffold is prepared in advance with the necessary biochemical properties to enhance its reliability and reduce failure rates while maintaining infection resistance.

The patent employs continuity of useful action by ensuring that the biologically active molecules remain functional and active throughout the implantation process and over time. The functionalization is designed to be stable and持久, maintaining the scaffold's ability to promote tissue integration and resist infection continuously. This continuous functional activity ensures sustained reliability and reduces the risk of failure and bacterial infection over the long term.

The patent applies the taking out principle by extracting and localizing the antibiotic function directly to the implant site rather than relying on systemic administration. Biologically active molecules including antibiotics are immobilized specifically on the decellularized organ scaffold at the implant location. This localized delivery extracts the antibiotic function from the systemic circulation and concentrates it at the site of need, eliminating the requirement for continuous systemic monitoring while maintaining effective infection treatment.

The patent employs self-service by designing the scaffold to autonomously deliver and maintain therapeutic concentrations of biologically active molecules at the implant site without requiring external monitoring or intervention. The immobilized molecules are released in a controlled manner based on the local biological environment, allowing the implant to self-regulate its therapeutic function. This self-service approach eliminates the need for continuous clinical monitoring of drug levels while ensuring effective infection treatment.